PUBLIC COMPANY
saveBIOCRYST
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- Novartis subsidiary Avidity will lay off 40 in San DiegoFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 4h ago
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 2mo ago
- BioCryst ends internal discovery programs, will close Alabama research facilityBioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal disc…endpoints · 4mo ago
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...endpoints · 6mo ago
- Chiesi to buy KalVista in $1.9B deal for rare disease drugThe acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.biopharma_dive · 6mo ago
- Fierce Biotech Layoff Tracker 2026: Agios trims 100 R&D roles; Ultragenyx lays off 20%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 10mo ago
comments(0)
5-min edit window · permanent after that